Abstract
The new coronavirus infection pandemic entered our lives rapidly and comorbid diseases were defined for this infection, which progressed with severe lung involvement. Due to its multifactorial pathophysiology, asthma has become one of the most curious and researched diseases and its comorbidity in COVID-19 is controversial. Although there are hypotheses in the literature stating that allergic asthma is protective, there are also hypotheses that argue that if the patient develops symptoms in allergic asthma, the course will be more severe. Our 20-year-old patient, who was diagnosed with allergic asthma, had a history of incomplete allergen immunotherapy, and whose symptoms were under control with omalizumab for 1 year, survived the COVID-19 infection without developing cough or other asthma attack symptoms, without being admitted to hospital. By presenting this case, we wanted to contribute to the understanding of the relationship between asthma, omalizumab treatment and COVID-19.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
